Arbutus Biopharma Past Earnings Performance
Past criteria checks 0/6
Arbutus Biopharma has been growing earnings at an average annual rate of 16.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 20.1% per year.
Key information
16.6%
Earnings growth rate
44.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 20.1% |
| Return on equity | -71.8% |
| Net Margin | -1,137.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Revenue & Expenses Breakdown
How Arbutus Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 7 | -77 | 22 | 0 |
| 30 Jun 24 | 10 | -77 | 24 | 0 |
| 31 Mar 24 | 13 | -74 | 22 | 0 |
| 31 Dec 23 | 18 | -73 | 22 | 0 |
| 30 Sep 23 | 22 | -75 | 22 | 0 |
| 30 Jun 23 | 24 | -73 | 19 | 0 |
| 31 Mar 23 | 33 | -70 | 18 | 0 |
| 31 Dec 22 | 39 | -69 | 18 | 0 |
| 30 Sep 22 | 36 | -69 | 18 | 0 |
| 30 Jun 22 | 33 | -76 | 19 | 0 |
| 31 Mar 22 | 21 | -85 | 18 | 0 |
| 31 Dec 21 | 11 | -88 | 17 | 0 |
| 30 Sep 21 | 10 | -87 | 16 | 0 |
| 30 Jun 21 | 8 | -84 | 16 | 0 |
| 31 Mar 21 | 8 | -79 | 15 | 0 |
| 31 Dec 20 | 7 | -76 | 15 | 0 |
| 30 Sep 20 | 6 | -83 | 13 | 0 |
| 30 Jun 20 | 8 | -147 | 10 | 0 |
| 31 Mar 20 | 7 | -156 | 13 | 0 |
| 31 Dec 19 | 6 | -165 | 14 | 0 |
| 30 Sep 19 | 6 | -158 | 18 | 0 |
| 30 Jun 19 | 5 | -100 | 20 | 0 |
| 31 Mar 19 | 5 | -73 | 17 | 0 |
| 31 Dec 18 | 6 | -67 | 16 | 0 |
| 30 Sep 18 | 7 | -83 | 14 | 0 |
| 30 Jun 18 | 12 | -68 | 15 | 0 |
| 31 Mar 18 | 12 | -86 | 15 | 0 |
| 31 Dec 17 | 11 | -85 | 16 | 0 |
| 30 Sep 17 | 8 | -267 | 16 | 0 |
| 30 Jun 17 | 2 | -275 | 14 | 0 |
| 31 Mar 17 | 1 | -387 | 15 | 0 |
| 31 Dec 16 | 1 | -384 | 13 | 0 |
| 30 Sep 16 | 14 | -171 | 14 | 0 |
| 30 Jun 16 | 18 | -180 | 12 | 0 |
| 31 Mar 16 | 21 | -65 | 14 | 0 |
| 31 Dec 15 | 23 | -63 | 26 | 0 |
| 30 Sep 15 | 17 | -62 | 13 | 0 |
| 30 Jun 15 | 17 | -42 | 15 | 0 |
| 31 Mar 15 | 15 | -33 | 9 | 0 |
| 31 Dec 14 | 15 | -39 | 9 | 0 |
| 30 Sep 14 | 18 | -35 | 8 | 0 |
| 30 Jun 14 | 17 | -33 | 8 | 0 |
| 31 Mar 14 | 18 | -30 | 7 | 0 |
Quality Earnings: ABUS is currently unprofitable.
Growing Profit Margin: ABUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABUS is unprofitable, but has reduced losses over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare ABUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: ABUS has a negative Return on Equity (-71.76%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 09:35 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arbutus Biopharma Corporation is covered by 27 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Brian Skorney | Baird |
| David Martin | Bloom Burton & Co. |